Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Florence Joulain"'
Autor:
Florence Joulain, Yurie Taguchi, Ichiro Arakawa, Hisako Matsumoto, Masanori Miyata, Maki Ueyama, Yuji Tohda
Background: Asthma is a common, chronic inflammatory airway disorder, with up to 1,177,000 people receiving asthma treatment in Japan. Dupilumab is a first-in-class, monoclonal antibody for the treatment of atopic diseases, including persistent asthm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6322ca0aac2cb127b8393858eb4f4b0f
Autor:
Deepak L. Bhatt, Andrew H. Briggs, Shelby D. Reed, Lieven Annemans, Michael Szarek, Vera A. Bittner, Rafael Diaz, Shaun G. Goodman, Robert A. Harrington, Keiko Higuchi, Florence Joulain, J. Wouter Jukema, Qian H. Li, Kenneth W. Mahaffey, Robert J. Sanchez, Matthew T. Roe, Renato D. Lopes, Harvey D. White, Andreas M. Zeiher, Gregory G. Schwartz, Ph. Gabriel Steg, Pierluigi Tricoci, Jay M. Edelberg, Corinne Hanotin, Guillaume Lecorps, Angèle Moryusef, Robert Pordy, William J. Sasiela, Jean-François Tamby
Publikováno v:
Journal of the American College of Cardiology. 75:2297-2308
Background Cholesterol reduction with proprotein convertase subtilisin-kexin type 9 inhibitors reduces ischemic events; however, the cost-effectiveness in statin-treated patients with recent acute coronary syndrome remains uncertain. Objectives This
Autor:
Florence Joulain, Johann S. de Bono, Christine Geffriaud-Ricouard, Anders Widmark, Oliver Sartor
Publikováno v:
Nowotwory. Journal of Oncology. 64:1-6
Cel . Niniejsza analiza — wtorna do badania TROPIC — ma na celu ocene czasu przezycia calkowitego ( overall survival , OS) po zastosowaniu kabazytakselu w podgrupach chorych, u ktorych od początku nie uzyskano odpowiedzi na docetaksel (D) i odst
Autor:
Hans-Joachim Schmoll, Emmanuelle Dochy, Cristina Grávalos, Joseph McKendrick, David Cunningham, Paul Ruff, Guy van Hazel, Michael L. Andria, Eric Van Cutsem, Radek Lakomý, Raghu L. Vishwanath, Solenn Le-Guennec, Dirk Arnold, Edith P. Mitchell, Teresa Macarulla, Florence Joulain, Vladimir Moiseyenko, Jana Prausová, H. Kröning, Paulo M. Hoff, Josep Tabernero, Yves Humblet, Albert J. ten Tije
Publikováno v:
Targeted oncology. 11(3)
The aim of this post hoc analysis of the VELOUR study (ClinicalTrials.gov NCT00561470) was to investigate the treatment effect of adding aflibercept to second-line infusional 5-fluorouracil (5-FU), leucovorin and irinotecan (FOLFIRI) in patients with
Autor:
Florence Joulain, Enrique P. Gurfinkel, Ari Timerman, Marc Cohen, Giancarlo Corsini, Kurt Huber, Pierfranco Terrosu, Gian Franco Gensini, Jose Santopinto, Frans Maritz
Publikováno v:
Journal of Thrombosis and Thrombolysis. 19:155-161
The standard of care for ST-segment elevation myocardial infarction (STEMI) is prompt coronary reperfusion with thrombolysis or percutaneous coronary intervention. Women have higher mortality rates than men following STEMI and fewer women are conside
Autor:
Florence Joulain, Andreas Kuznik, Khurram Nasir, Andrew Briggs, Robert J. Sanchez, Alexa Klimchak
Publikováno v:
Journal of the American College of Cardiology. 69:66
Background: Association between low-density lipoprotein cholesterol (LDL-C) and cardiovascular (CV) events is well established. We aim to model one-year benefits of additional LDL-C lowering with alirocumab on CV risk. Methods: Data from MarketScan w
Publikováno v:
BMC Cancer
Background The VELOUR study demonstrated a survival benefit for FOLFIRI + aflibercept versus FOLFIRI + placebo in metastatic colorectal cancer (mCRC) patients who progressed on oxaliplatin-based chemotherapy. Continued divergence of overall survival
Autor:
E. Van Cutsem, Josep Tabernero, Sheikh Usman Iqbal, Martin Hoyle, Florence Joulain, Irina Proskorovsky, Carmen J. Allegra
Publikováno v:
British Journal of Cancer
Background: Mean survival in cancer trials can be estimated with statistical techniques to extrapolate study survival curves. This methodology was applied to data from the VELOUR trial, where use of the novel biologic aflibercept (ziv-aflibercept in
Autor:
Y. Moore, Chiara Zilocchi, Anne L. Thomas, Gérard Lledo, P. García Alfonso, Katia Bencardino, Emmanuelle Dochy, Sandrine Brette, F. Di Costanzo, H. Kröning, Alberto Sobrero, Ludovica Ciuffreda, M. Di Bartolomeo, Sarah Naoshy, Pascale Garreau-Laporte, Julien Taieb, Christophe Borg, Roberto Bordonaro, Florence Joulain
Publikováno v:
Annals of Oncology. 25:iv180
Aim: In the phase 3 VELOUR trial, aflibercept (ziv-aflibercept in the United States) + FOLFIRI significantly improved overall survival vs FOLFIRI alone in metastatic colorectal cancer (mCRC) patients (pts) previously treated with an oxaliplatin-conta
Autor:
Guy van Hazel, Paulo M. Hoff, Raghu L. Vishwanath, Sarah Naoshy, Hans J. Schmoll, Edith P. Mitchell, Dirk Arnold, Albert J. ten Tije, Joseph McKendrick, David Cunningham, Florence Joulain, Emmanuelle Dochy
Publikováno v:
Journal of Clinical Oncology. 32:3639-3639
3639 Background: The addition of B to an oxaliplatin-based regimen in 1st line metastatic colorectal cancer (mCRC) pts has shown a median progression free survival (PFS) of 9.4 mos as seen in NO16966. In the ML18147 study, the benefit of B added to c